NCT03051841View on ClinicalTrials.gov

CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma

PHASE1UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

April 30, 2021

Study Completion Date

November 30, 2022

Conditions
Myeloma, Multiple
Interventions
DRUG

CKD-581

Intravenously on Days 1, 8 of each 21-day treatment cycle.

Trial Locations (1)

Unknown

RECRUITING

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY